Home/Pipeline/Insulin Glargine Biosimilar

Insulin Glargine Biosimilar

Diabetes

PreclinicalActive

Key Facts

Indication

Diabetes

Phase

Preclinical

Status

Active

Company

Meitheal Pharmaceuticals

About Meitheal Pharmaceuticals

Meitheal Pharmaceuticals is a private, commercial-stage biopharma company focused on generic injectables and biosimilars. Leveraging a partnership-driven model, it has built a diverse pipeline and product portfolio targeting therapeutic areas such as anti-infectives, oncology, diabetes, fertility, and immunology. The company emphasizes robust manufacturing, steady supply, and rapid market response to address unmet needs and improve drug affordability. Its recent expansion into biosimilars with the acquisition of YUSIMRY® and launch of products like liraglutide injection signals a strategic growth phase.

View full company profile

Therapeutic Areas

Anti-Infective Oncology Immunology & Inflammation Fertility Diabetes

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
Oral Insulin	Premas Biotech	Phase 3	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active
Glucose-Responsive Insulin Receptor Agonist	Protomer Technologies	Pre-clinical (integrated into Lilly pipeline)	Active